clinical

DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize Diverse Clinical and Multi-omics Data

Leading cloud-based enterprise platform for precision health data empowers biopharma companies with actionable insights to accelerate drug discovery and development     SAN ANTONIO,…

8 hours ago

DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize Diverse Clinical and Multi-omics Data

Leading cloud-based enterprise platform for precision health data empowers biopharma companies with actionable insights to accelerate drug discovery and development     SAN ANTONIO,…

1 day ago

DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize Diverse Clinical and Multi-omics Data

Leading cloud-based enterprise platform for precision health data empowers biopharma companies with actionable insights to accelerate drug discovery and development     SAN ANTONIO,…

2 days ago

DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize Diverse Clinical and Multi-omics Data

Leading cloud-based enterprise platform for precision health data empowers biopharma companies with actionable insights to accelerate drug discovery and development     SAN ANTONIO,…

3 days ago

DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize Diverse Clinical and Multi-omics Data

Leading cloud-based enterprise platform for precision health data empowers biopharma companies with actionable insights to accelerate drug discovery and development     SAN ANTONIO,…

4 days ago

NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology

NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational…

4 days ago

Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg

– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with…

5 days ago

Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg

– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with…

6 days ago

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling…

6 days ago

Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

December 09, 2024 12:00 ET | Source: Disc Medicine Inc  Positive updates across all programs, including updates from ongoing clinical…

2 weeks ago